News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

In May 2024, Google DeepMind released AlphaFold 3, a game changing protein folding model that predicts with 50% better ...

Under the brand name Kisqali, ribociclib has been approved in the US as a first line treatment for certain breast cancer patients, meaning Pfizer’s big-selling rival faces competition for the ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how to approach treatment after progression on first-line therapy and hormone receptor-positive ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at American Society of Nephrology Kidney Week 2024 showing that patients with C3 glomerulopathy treated with oral ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...